Humana delivered first-quarter results that exceeded analyst projections on Wednesday, yet shareholders responded with disappointment. The health insurance provider saw its shares tumble as much as 7.4% in early trading after declining to raise its annual profit guidance while competitors boosted their own forecasts.
The company reported adjusted earnings of $10.31 per share, surpassing Wall Street’s consensus estimate of approximately $10.19–$10.20. Revenue climbed to $39.65 billion from $32.11 billion in the prior-year period, also exceeding the anticipated $39.37 billion.
However, the positive earnings surprise failed to boost investor confidence.
According to Julie Utterback, an analyst at Morningstar, market participants likely anticipated that Humana would increase its forward guidance following such a robust quarterly performance. Instead, the company stood pat.
Management reaffirmed its full-year adjusted earnings projection of at least $9 per share. Notably, the reported earnings outlook was actually lowered — revised down to at least $8.36 per share from the prior expectation of at least $8.89.
This downward revision accounts for expenses associated with a multiyear restructuring initiative, encompassing severance payments, asset write-downs, and external consulting fees.
Central to Humana’s challenges are its diminished Medicare Advantage Star Ratings for 2026. These government-issued ratings, ranging from one to five stars, directly determine bonus compensation from federal authorities. Reduced ratings translate to smaller bonus payments.
The insurer has been communicating this obstacle for several quarters. First-quarter net income totaled $9.83 per share, declining from $10.30 in the same period last year — a clear indicator of this ongoing pressure.
CEO Jim Rechtin confirmed that medical utilization and associated costs aligned with internal projections. However, he emphasized that the differential between the company’s healthcare spending and government reimbursement rates has expanded year-over-year.
“Every year we’re going to step back and look at our whole portfolio,” Rechtin said.
Amid the challenges, one encouraging metric emerged: Humana’s insurance division’s benefit ratio — representing the percentage of premium revenue allocated to medical expenses — registered 89.4% for the first quarter. This figure came in better than the company’s internal forecast of just under 90% and beat Wall Street’s expectation of 89.7%.
A lower ratio benefits insurers significantly. Readings below 90% typically indicate effective cost management.
Looking ahead to the second quarter, Humana projects this ratio will increase to slightly above 91%, suggesting upcoming cost pressures.
The organization also observed that aggregate medical and pharmacy cost trends are performing marginally better than anticipated, which Cantor analyst Sarah James identified as among the limited positives in the quarterly report.
Nevertheless, James raised red flags. “HUM has several signals that the back-half of the year could be difficult to manage,” she noted, characterizing the premarket decline as “a warning sign.”
Humana indicated it will modify benefit structures as necessary to preserve stable profit margins. The federal government recently announced a 2.48% average increase in Medicare Advantage reimbursement rates for 2027.
Shares were trading down approximately 2% in premarket activity after the initial 7.4% decline.
The post Humana (HUM) Stock Tumbles Despite Q1 Earnings Beat Amid Unchanged Guidance appeared first on Blockonomi.
